Bradley Duffy

Array ( [id] => 20419080 [patent_doc_number] => 20250381165 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-12-18 [patent_title] => Method of Use for Benzofuran Compounds [patent_app_type] => utility [patent_app_number] => 19/217172 [patent_app_country] => US [patent_app_date] => 2025-05-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 27709 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 48 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19217172 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20136236 [patent_doc_number] => 20250243280 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-07-31 [patent_title] => METHODS OF TREATING GASTROINTESTINAL INFLAMMATORY DISEASE [patent_app_type] => utility [patent_app_number] => 19/182382 [patent_app_country] => US [patent_app_date] => 2025-04-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 39637 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 78 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19182382 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19998485 [patent_doc_number] => 20250136707 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-05-01 [patent_title] => BISPECIFIC CHIMERIC ANTIGEN RECEPTORS TARGETING CD20 AND BCMA [patent_app_type] => utility [patent_app_number] => 19/006633 [patent_app_country] => US [patent_app_date] => 2024-12-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17064 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 111 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19006633 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19998485 [patent_doc_number] => 20250136707 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-05-01 [patent_title] => BISPECIFIC CHIMERIC ANTIGEN RECEPTORS TARGETING CD20 AND BCMA [patent_app_type] => utility [patent_app_number] => 19/006633 [patent_app_country] => US [patent_app_date] => 2024-12-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17064 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 111 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19006633 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19931759 [patent_doc_number] => 12304956 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2025-05-20 [patent_title] => Dosing regimen for treating inflammatory bowel disease [patent_app_type] => utility [patent_app_number] => 18/774123 [patent_app_country] => US [patent_app_date] => 2024-07-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 17 [patent_figures_cnt] => 28 [patent_no_of_words] => 39860 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 188 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18774123 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19657007 [patent_doc_number] => 20240424072 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-12-26 [patent_title] => Albumin Bound Macromolecule Tri-Agonist Activating GLP 1/GIP/Glucagon Receptors And Methods Therefor [patent_app_type] => utility [patent_app_number] => 18/753928 [patent_app_country] => US [patent_app_date] => 2024-06-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17710 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 94 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18753928 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19657007 [patent_doc_number] => 20240424072 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-12-26 [patent_title] => Albumin Bound Macromolecule Tri-Agonist Activating GLP 1/GIP/Glucagon Receptors And Methods Therefor [patent_app_type] => utility [patent_app_number] => 18/753928 [patent_app_country] => US [patent_app_date] => 2024-06-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17710 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 94 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18753928 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19556751 [patent_doc_number] => 20240368543 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-11-07 [patent_title] => TREATMENT OF NSCLC PATIENTS WITH TUMOR INFILTRATING LYMPHOCYTE THERAPIES [patent_app_type] => utility [patent_app_number] => 18/674755 [patent_app_country] => US [patent_app_date] => 2024-05-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 223289 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18674755 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19389484 [patent_doc_number] => 20240279354 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-08-22 [patent_title] => CHIMERIC POLYPEPTIDE ASSEMBLY AND METHODS OF MAKING AND USING THE SAME [patent_app_type] => utility [patent_app_number] => 18/626607 [patent_app_country] => US [patent_app_date] => 2024-04-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 87596 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18626607 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19002051 [patent_doc_number] => 20240066122 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-02-29 [patent_title] => METHODS AND COMPOSITIONS FOR ADOPTIVE CELL THERAPY [patent_app_type] => utility [patent_app_number] => 18/491633 [patent_app_country] => US [patent_app_date] => 2023-10-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 51623 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 123 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18491633 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18877476 [patent_doc_number] => 20240000845 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-01-04 [patent_title] => OPTIMIZED ENGINEERED NUCLEASES HAVING SPECIFICITY FOR THE HUMAN T CELL RECEPTOR ALPHA CONSTANT REGION GENE [patent_app_type] => utility [patent_app_number] => 18/461190 [patent_app_country] => US [patent_app_date] => 2023-09-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 30858 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -96 [patent_words_short_claim] => 127 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18461190 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18923012 [patent_doc_number] => 20240026016 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-01-25 [patent_title] => SELF-ANTIGEN SPECIFIC T-CELLS AS VACCINES FOR AUGMENTING ENGRAFTMENT AND STABILITY OF AUTOLOGOUS TRANSFER [patent_app_type] => utility [patent_app_number] => 18/344214 [patent_app_country] => US [patent_app_date] => 2023-06-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16634 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18344214 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18902726 [patent_doc_number] => 20240018211 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-01-18 [patent_title] => EXOSOME COMPRISING OVEREXPRESSED FC RECEPTOR OR PORTION THEREOF, AND METHOD FOR PREPARING SAME [patent_app_type] => utility [patent_app_number] => 18/329960 [patent_app_country] => US [patent_app_date] => 2023-06-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9166 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 105 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18329960 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20348572 [patent_doc_number] => 20250345424 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-11-13 [patent_title] => TREATMENT OF AUTOIMMUNE DISEASES WITH ENGINEERED IMMUNE CELLS [patent_app_type] => utility [patent_app_number] => 18/390978 [patent_app_country] => US [patent_app_date] => 2023-06-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5606 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18390978 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20348572 [patent_doc_number] => 20250345424 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-11-13 [patent_title] => TREATMENT OF AUTOIMMUNE DISEASES WITH ENGINEERED IMMUNE CELLS [patent_app_type] => utility [patent_app_number] => 18/390978 [patent_app_country] => US [patent_app_date] => 2023-06-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5606 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18390978 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19050958 [patent_doc_number] => 20240092927 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-03-21 [patent_title] => Subcutaneous Formulations Of Anti-CD38 Antibodies And Their Uses [patent_app_type] => utility [patent_app_number] => 18/329562 [patent_app_country] => US [patent_app_date] => 2023-06-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 23339 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18329562 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19050958 [patent_doc_number] => 20240092927 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-03-21 [patent_title] => Subcutaneous Formulations Of Anti-CD38 Antibodies And Their Uses [patent_app_type] => utility [patent_app_number] => 18/329562 [patent_app_country] => US [patent_app_date] => 2023-06-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 23339 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18329562 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18769437 [patent_doc_number] => 20230364201 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-11-16 [patent_title] => PHARMACEUTICAL COMPOSITION CONTAINING INSULIN-LIKE GROWTH FACTOR-2 AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 18/300286 [patent_app_country] => US [patent_app_date] => 2023-04-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7668 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -4 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18300286 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18769437 [patent_doc_number] => 20230364201 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-11-16 [patent_title] => PHARMACEUTICAL COMPOSITION CONTAINING INSULIN-LIKE GROWTH FACTOR-2 AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 18/300286 [patent_app_country] => US [patent_app_date] => 2023-04-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7668 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -4 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18300286 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18565741 [patent_doc_number] => 20230256068 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-08-17 [patent_title] => AMHR2-ED CANCER VACCINE FORMULATIONS [patent_app_type] => utility [patent_app_number] => 18/169293 [patent_app_country] => US [patent_app_date] => 2023-02-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9778 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -45 [patent_words_short_claim] => 41 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18169293 [rel_patent_id] =>[rel_patent_doc_number] =>)